---
title: "Novo Nordisk makes a comeback, stating that the cardiovascular benefits of the weight-loss version of semaglutide are superior to those of tirzepatide"
description: "Novo Nordisk AS announced the latest data from the STEER study at the 2025 European Society of Cardiology Congress, showing that the weight-loss version of semaglutide is more effective than tirzepati"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255409513.md"
published_at: "2025-09-01T06:33:51.000Z"
---

# Novo Nordisk makes a comeback, stating that the cardiovascular benefits of the weight-loss version of semaglutide are superior to those of tirzepatide

> Novo Nordisk AS announced the latest data from the STEER study at the 2025 European Society of Cardiology Congress, showing that the weight-loss version of semaglutide is more effective than tirzepatide in preventing major adverse cardiovascular events in patients with cardiovascular disease. The study indicates that patients using the weight-loss version of semaglutide have a 57% reduced risk of heart attack, stroke, and cardiovascular-related death

In the competition of GLP-1 weight loss drugs, Novo Nordisk's semaglutide has finally turned the tide with its cardiovascular benefits. On September 1st, reporters learned from Novo Nordisk China that the company announced the latest data from the STEER real-world study at the 2025 European Society of Cardiology Congress held in Madrid, Spain. The STEER study is a retrospective, observational real-world study that evaluated the effectiveness of Wegovy compared to tirzepatide in preventing major adverse cardiovascular events in overweight or obese patients with diagnosed cardiovascular disease but without diabetes. The results showed that, under the condition that the medication interruption during treatment did not exceed 30 days, the weight loss version of semaglutide reduced the risk of heart attack, stroke, and cardiovascular-related death or all-cause mortality by 57% compared to tirzepatide in overweight or obese patients with cardiovascular disease. In the trial, the semaglutide group recorded 15 cardiovascular events, while the tirzepatide group recorded 39 events

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 諾和諾德公司確認收到 FDA 關於 Wegovy 藥片電視廣告的 “未命名信函” | 諾和諾德公司：確認諾和諾德收到美國食品藥品監督管理局（FDA）關於 WEGOVY 藥丸電視廣告的 “未命名信函” 諾和諾德公司：正在與 FDA 溝通，以解決他們對 WEGOVY 藥丸廣告展示的擔憂諾和諾德公司：確認諾和諾德收到美國食品藥品監 | [Link](https://longbridge.com/en/news/275349213.md) |
| Berenberg 銀行重申其對諾和諾德公司（0QIU）的買入評級 | Berenberg Bank 分析師 Kerry Holford 重申了對諾和諾德公司 (0QIU) 的買入評級，目標價為 360.00 丹麥克朗。Holford 是一位四星級分析師，成功率為 59.14%，專注於醫療保健領域。最近，德意志 | [Link](https://longbridge.com/en/news/275719942.md) |
| 諾和諾德公司首席財務官 Karsten Munk Knudsen 出售了價值超過 830 萬丹麥克朗的股票 | 諾和諾德公司（Novo Nordisk A/S）宣佈，首席財務官卡斯滕·穆克·克努森（Karsten Munk Knudsen）於 2026 年 2 月 10 日以每股 DKK 315.60 的價格出售了 26,246 股，交易總額為 DK | [Link](https://longbridge.com/en/news/275652909.md) |
| 諾和諾德公司將在其愛爾蘭工廠生產 Wegovy | 諾和諾德公司將在愛爾蘭工廠生產 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| Biocon 計劃通過推出仿製減肥藥來推動收入大幅增長 | Biocon 計劃通過全球推出包括諾和諾德的 Wegovy 和利拉魯肽在內的仿製減肥藥，實現高雙位數的收入增長。該公司計劃在下一個財年在美國推出利拉魯肽，並在加拿大推出 Wegovy，同時由於激烈的價格競爭和監管障礙，對進入印度市場持謹慎態 | [Link](https://longbridge.com/en/news/275900960.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
